The Features of the Clinical Course and Treatment of Moderately Severe Graves’ Ophthalmopathy in Patients with Graves’ Disease in Response to Catamnesis

Objective. To document the course of Graves’ ophthalmopathy (GO), following immunosuppressive therapy and the spontaneous course of the disease in patients with Graves’ disease (GD). Design. Randomized study with three-year follow-up. Patients. 150 euthyroid patients with moderately severe GO. Inter...

Full description

Bibliographic Details
Format: Article
Language:Russian
Published: Endocrinology Research Centre 2005-03-01
Series:Клиническая и экспериментальная тиреоидология
Online Access:https://cet-endojournals.ru/ket/article/view/4312
id doaj-568f9eb2e73749069b00cc559efe78a3
record_format Article
spelling doaj-568f9eb2e73749069b00cc559efe78a32021-06-02T21:40:29ZrusEndocrinology Research CentreКлиническая и экспериментальная тиреоидология1995-54722310-37872005-03-0111364210.14341/ket20051136-424270The Features of the Clinical Course and Treatment of Moderately Severe Graves’ Ophthalmopathy in Patients with Graves’ Disease in Response to CatamnesisObjective. To document the course of Graves’ ophthalmopathy (GO), following immunosuppressive therapy and the spontaneous course of the disease in patients with Graves’ disease (GD). Design. Randomized study with three-year follow-up. Patients. 150 euthyroid patients with moderately severe GO. Intervention. In group 1 (n = 52) patients received glucocorticoids (GC) alone (prednisolone per os for 5 months, starting dose, 50—80 mg/d; or intravenous, 500—1000 mg/d, given during 3 days weekly; 5—6 cycles in all). Group 2 (n = 51) treated by GC in combination with orbital radiotherapy (16—20 Gy). None of 47 patients of group 3 treated with immunosuppressive therapy either due to contraindications to corticosteroids, or refusal of patients (spontaneous course of GO). Measurements: The activity of GO was scored by the method of Mourits et al., 1997, (Clinical Activity Score, CAS) and confirmed by the assessment of serum sICAM-1 (soluble form of intercellular adhesion molecule-1) and uGAGs (the urinary excretion of glycosaminoglycans). Results. Group 2 was characterized with the earliest establishment of the inactive GO (CAS J 2) (in 2.7 ± 1.4 months after beginning of the treatment) (p 0.05), and the lowest frequency of deteriorations (p 0,05). In the end of observation the “burnt out” stage of GO (fibrosis) was revealed in 98% of patients of group 2, that statistically differs from two other groups (p 0.001). Group 3, in this respect, statistically did not differ from group 1 (45% vs 38%, P = 0.39), detected by comparison of CAS values, uGAGs, sICAM-1, obtained in inactive GO. Conclusions. 1) the absence of statistical verified differences of parameters, obtained in the inactive GO in groups 3 and 1 allow to use active observation at the planning of GO treatment; 2) the most effective strategy of treatment of moderately severe GO should be considered combined immunosuppressive therapy. Key words: graves’disease, ophthalmopathy, hyperthyroidism.https://cet-endojournals.ru/ket/article/view/4312
collection DOAJ
language Russian
format Article
sources DOAJ
title The Features of the Clinical Course and Treatment of Moderately Severe Graves’ Ophthalmopathy in Patients with Graves’ Disease in Response to Catamnesis
spellingShingle The Features of the Clinical Course and Treatment of Moderately Severe Graves’ Ophthalmopathy in Patients with Graves’ Disease in Response to Catamnesis
Клиническая и экспериментальная тиреоидология
title_short The Features of the Clinical Course and Treatment of Moderately Severe Graves’ Ophthalmopathy in Patients with Graves’ Disease in Response to Catamnesis
title_full The Features of the Clinical Course and Treatment of Moderately Severe Graves’ Ophthalmopathy in Patients with Graves’ Disease in Response to Catamnesis
title_fullStr The Features of the Clinical Course and Treatment of Moderately Severe Graves’ Ophthalmopathy in Patients with Graves’ Disease in Response to Catamnesis
title_full_unstemmed The Features of the Clinical Course and Treatment of Moderately Severe Graves’ Ophthalmopathy in Patients with Graves’ Disease in Response to Catamnesis
title_sort features of the clinical course and treatment of moderately severe graves’ ophthalmopathy in patients with graves’ disease in response to catamnesis
publisher Endocrinology Research Centre
series Клиническая и экспериментальная тиреоидология
issn 1995-5472
2310-3787
publishDate 2005-03-01
description Objective. To document the course of Graves’ ophthalmopathy (GO), following immunosuppressive therapy and the spontaneous course of the disease in patients with Graves’ disease (GD). Design. Randomized study with three-year follow-up. Patients. 150 euthyroid patients with moderately severe GO. Intervention. In group 1 (n = 52) patients received glucocorticoids (GC) alone (prednisolone per os for 5 months, starting dose, 50—80 mg/d; or intravenous, 500—1000 mg/d, given during 3 days weekly; 5—6 cycles in all). Group 2 (n = 51) treated by GC in combination with orbital radiotherapy (16—20 Gy). None of 47 patients of group 3 treated with immunosuppressive therapy either due to contraindications to corticosteroids, or refusal of patients (spontaneous course of GO). Measurements: The activity of GO was scored by the method of Mourits et al., 1997, (Clinical Activity Score, CAS) and confirmed by the assessment of serum sICAM-1 (soluble form of intercellular adhesion molecule-1) and uGAGs (the urinary excretion of glycosaminoglycans). Results. Group 2 was characterized with the earliest establishment of the inactive GO (CAS J 2) (in 2.7 ± 1.4 months after beginning of the treatment) (p 0.05), and the lowest frequency of deteriorations (p 0,05). In the end of observation the “burnt out” stage of GO (fibrosis) was revealed in 98% of patients of group 2, that statistically differs from two other groups (p 0.001). Group 3, in this respect, statistically did not differ from group 1 (45% vs 38%, P = 0.39), detected by comparison of CAS values, uGAGs, sICAM-1, obtained in inactive GO. Conclusions. 1) the absence of statistical verified differences of parameters, obtained in the inactive GO in groups 3 and 1 allow to use active observation at the planning of GO treatment; 2) the most effective strategy of treatment of moderately severe GO should be considered combined immunosuppressive therapy. Key words: graves’disease, ophthalmopathy, hyperthyroidism.
url https://cet-endojournals.ru/ket/article/view/4312
_version_ 1721400321238892544